Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated with Clinical Activity.
Clin Cancer ResOct 1, 2026
Sriram Sridhar, M Guy Roukens, Christina Y Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II multicenter trial evaluated the efficacy of tisotumab vedotin (TV) in patients with recurrent or metastatic cervical cancer (r/mCC). The study found that higher expression of immune-related gene signatures, particularly those linked to natural killer and myeloid cells, was associated with improved clinical outcomes, despite tissue factor (TF) expression not correlating with response.
Key findings
- Higher expression of immune-related gene signatures linked to NK and myeloid cells was associated with improved clinical outcomes.
- TF expression did not correlate with clinical response in patients treated with TV.
- TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels.
Why it matters
Understanding the immune pathways associated with clinical activity of tisotumab vedotin can inform treatment strategies and patient selection in recurrent or metastatic cervical cancer, potentially enhancing therapeutic efficacy.